Chordoma and chondrosarcoma gene profile: implications for immunotherapy

  • Joseph H. Schwab
  • Patrick J. Boland
  • Narasimhan P. Agaram
  • Nicholas D. Socci
  • Tianhua Guo
  • Gary C. O’Toole
  • Xinhui Wang
  • Elena Ostroumov
  • Christopher J. Hunter
  • Joel A. Block
  • Stephen Doty
  • Soldano Ferrone
  • John H. Healey
  • Cristina R. Antonescu
Original Article

DOI: 10.1007/s00262-008-0557-7

Cite this article as:
Schwab, J.H., Boland, P.J., Agaram, N.P. et al. Cancer Immunol Immunother (2009) 58: 339. doi:10.1007/s00262-008-0557-7

Abstract

Chordoma and chondrosarcoma are malignant bone tumors characterized by the abundant production of extracellular matrix. The resistance of these tumors to conventional therapeutic modalities has prompted us to delineate the gene expression profile of these two tumor types, with the expectation to identify potential molecular therapeutic targets. Furthermore the transcriptional profile of chordomas and chrondrosarcomas was compared to a wide variety of sarcomas as well as to that of normal tissues of similar lineage, to determine whether they express unique gene signatures among other tumors of mesenchymal origin, and to identify changes associated with malignant transformation. A HG-U133A Affymetrix Chip platform was used to determine the gene expression signature in 6 chordoma and 14 chondrosarcoma lesions. Validation of selected genes was performed by qPCR and immunohistochemistry (IHC) on an extended subset of tumors. By unsupervised clustering, chordoma and chondrosarcoma tumors grouped together in a genomic cluster distinct from that of other sarcoma types. They shared overexpression of many extracellular matrix genes including aggrecan, type II & X collagen, fibronectin, matrillin 3, high molecular weight-melanoma associated antigen (HMW-MAA), matrix metalloproteinaseMMP-9, and MMP-19. In contrast, T Brachyury and CD24 were selectively expressed in chordomas, as were Keratin 8,13,15,18 and 19. Chondrosarcomas are distinguished by high expression of type IX and XI collagen. Because of its potential usefulness as a target for immunotherapy, the expression of HMW-MAA was analyzed by IHC and was detected in 62% of chordomas and 48% of chondrosarcomas, respectively. Furthermore, western blotting analysis showed that HMW-MAA synthesized by chordoma cell lines has a structure similar to that of the antigen synthesized by melanoma cells. In conclusion, chordomas and chondrosarcomas share a similar gene expression profile of up-regulated extracellular matrix genes. HMW-MAA represents a potential useful target to apply immunotherapy to these tumors.

Keywords

Chordoma Chondrosarcoma Gene expression Extracellular matrix HMW-MAA 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Joseph H. Schwab
    • 1
  • Patrick J. Boland
    • 1
  • Narasimhan P. Agaram
    • 2
  • Nicholas D. Socci
    • 3
  • Tianhua Guo
    • 2
  • Gary C. O’Toole
    • 1
  • Xinhui Wang
    • 4
  • Elena Ostroumov
    • 5
  • Christopher J. Hunter
    • 5
  • Joel A. Block
    • 6
  • Stephen Doty
    • 7
  • Soldano Ferrone
    • 8
  • John H. Healey
    • 1
  • Cristina R. Antonescu
    • 2
  1. 1.Department of Surgery, Orthopedic ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Computational Biology CenterSloan-Kettering InstituteNew YorkUSA
  4. 4.Department of ImmunologyUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  5. 5.Department of Mechanical and Manufacturing Engineering Centre for Bioengineering Research and EducationUniversity of CalgaryCalgaryCanada
  6. 6.Rheumatology SectionRush University Medical CenterChicagoUSA
  7. 7.The Hospital for Special SurgeryNew YorkUSA
  8. 8.Departments of Surgery, of Immunology and of PathologyUniversity of Pittsburgh Cancer InstitutePittsburghUSA

Personalised recommendations